AuthorisedTherapeutic exploratory (Phase II)Interventional

A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

This clinical trial is testing a medicine called Imfinzi (durvalumab) for adults with non-small cell lung cancer that can be removed with surgery. Before having their operation, patients receive a combination of chemotherapy and immunotherapy to shrink the tumour. After surgery, doctors want to know if giving additional immunotherapy helps keep the cancer away for longer. Imfinzi works by helping your body's own immune system find and attack any remaining cancer cells. Researchers will compare how patients do, looking closely at how long they stay free of cancer, their overall survival, and their day-to-day quality of life, including symptoms like breathlessness. They will also look at blood tests to check for tiny traces of cancer DNA. This study will help doctors decide whether giving extra immunotherapy after surgery should become a standard treatment.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Oslo Universitetssykehus HF

Enrolment target

300

Start

16 Sep 2026

Non Small Cell Lung Cancer (NSCLC)

What is this study about?

Lung cancer is one of the most common cancers, and non-small cell lung cancer is the most frequent type. When this cancer is caught early enough, surgery to remove the tumour offers the best chance of clearing it. Often, doctors give treatments such as chemotherapy alongside immunotherapy before the operation. This aims to shrink the tumour and make surgery safer and more effective.

Even after successful surgery, there is a risk that microscopic cancer cells remain behind, which could cause the cancer to return later. This clinical trial, known as the ADIL study, is exploring whether having immunotherapy after surgery helps prevent the cancer from coming back. The medicine being tested is called Imfinzi, which is designed to boost the immune system so it can recognise and destroy hidden cancer cells.

During the study, researchers will carefully monitor participants to see if the extra treatment delays or prevents the cancer from returning. They will also assess whether it helps people live longer, healthier lives. Alongside medical scans, the study team will track everyday wellbeing, looking specifically at energy levels and breathing, as well as testing blood samples for tiny traces of tumour DNA.

Finding out whether extra treatment after surgery is truly helpful is vital. It helps doctors understand if the benefits of extra medicine outweigh the time, clinic visits, and possible side effects, ensuring future lung cancer patients receive the best possible care.

Key takeaways

The ADIL trial is testing if an immunotherapy drug called Imfinzi after surgery helps stop lung cancer returning.
It is for adults with non-small cell lung cancer who had chemo-immunotherapy before surgery.
The drug is given as a drip into a vein at regular hospital visits.
Researchers will track cancer recurrence, survival, breathing, and quality of life.
Taking part is completely voluntary and you can leave at any time.

Who may be eligible?

This trial is open to adults aged 18 and over who have been diagnosed with non-small cell lung cancer that is suitable for surgery. To be considered, patients must have already received a combination of chemotherapy and immunotherapy before their operation.

Both men and women may take part. Because the trial involves an operation, participants need to be well enough to undergo surgery and tolerate further medication afterwards. Your hospital doctor will check your overall fitness and lung health.

People whose cancer has spread too far to be safely removed with surgery, or those with certain other medical conditions that make immunotherapy unsafe, will not be able to join. Your cancer care team can look at your medical records to confirm whether you meet all the safety checks.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am aged 18 or older.
I have been diagnosed with non-small cell lung cancer.
My cancer is considered operable (can be removed by surgery).
I have received chemo-immunotherapy before my planned operation.
I am well enough to attend regular hospital appointments for infusions and scans.

Answer every question to see your result.

What does participation involve?

Taking part in this study begins after your lung surgery. If you join, you will receive the study medicine, Imfinzi, as a liquid drip directly into a vein (an intravenous infusion) at the hospital clinic. Each infusion usually takes around an hour, and you will receive them at regular intervals planned by your trial team.

Throughout the study, you will have routine hospital appointments. These visits include blood tests, physical checks, and regular imaging scans (such as CT scans) to check on your chest and overall health. The team will also take blood samples to look for microscopic traces of cancer DNA, which helps show how well the treatment is working.

You will be asked to fill out simple questionnaires about your daily life, asking about your general energy and whether you experience any breathlessness. Follow-up appointments will continue for several years after surgery to monitor your recovery and long-term health.

Potential risks and benefits

The main hope of taking part is that the treatment may lower the chance of your cancer returning and help you stay well for longer, though this cannot be guaranteed. You will also receive very close health monitoring from a dedicated hospital team. However, Imfinzi can cause side effects. Because it stimulates the immune system, it can cause tiredness, cough, skin rashes, or inflammation in organs such as the lungs, bowel, or liver. Your team will watch you closely and treat any problems quickly. Joining the trial is entirely your choice, and you can change your mind and leave at any time without your normal NHS care being affected.

Locations (3)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Sweden
—
Unverified
Norway
—
Unverified
Denmark

Common questions

What is immunotherapy?

Immunotherapy is a type of cancer treatment that helps your body's natural defence system (the immune system) recognise and fight cancer cells.

How is the trial drug given?

Imfinzi is given through a small drip into a vein in your arm, usually at a day clinic in the hospital.

Will taking part affect my surgery?

No, your planned surgery goes ahead as normal. The extra trial treatment is given after you have recovered from your operation.

Do I have to pay for the trial medication?

No, clinical trial medicines are provided free of charge, and taking part will not cost you anything extra.

Can I leave the study if I change my mind?

Yes. You are free to stop taking part at any point, and your doctors will continue to give you the best standard care available.